

# Neuronal Acetylcholine Receptor Subunit Alpha 4 - Drugs In Development, 2021

<https://marketpublishers.com/r/N93D3ACCE20DEN.html>

Date: July 2021

Pages: 62

Price: US\$ 3,500.00 (Single User License)

ID: N93D3ACCE20DEN

## Abstracts

Neuronal Acetylcholine Receptor Subunit Alpha 4 - Drugs In Development, 2021

### SUMMARY

According to the recently published report 'Neuronal Acetylcholine Receptor Subunit Alpha 4 - Drugs In Development, 2021'; Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes.

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Neuronal acetylcholine receptor subunit alpha 4 or nAChRa4 is a protein encoded by the CHRNA4 gene. It plays a role in fast signal transmission at synapses. Receptors after binding of acetylcholine extensive change conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.

The report 'Neuronal Acetylcholine Receptor Subunit Alpha 4 - Drugs In Development, 2021' outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-

Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1, 4 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Smoking Cessation, Alcohol Addiction, Major Depressive Disorder, Nicotine Addiction and Psychiatric Disorders.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)

The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics and enlists all their major and minor projects

The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Overview

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Companies Involved in  
Therapeutics Development

Assuage Pharmaceuticals Inc

Ctcbio Inc

Jeil Pharmaceutical Co Ltd

Kyung Dong Co Ltd

Sobrero Pharma AB

Sopharma AD

Suven Life Sciences Ltd

Yuhan Corp

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Drug Profiles  
(varenicline tartrate + bupropion hydrochloride) SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDFE-0318 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cytisinicline - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JLP-1603 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KD-8001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize CHRN2 and CHRNA4 for Psychiatric Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CHRN2 and CHRNA4 for Smoking Cessation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVN-911 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

varenicline tartrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

varenicline tartrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Dormant Products

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Discontinued Products

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Product Development

Milestones

## Featured News & Press Releases

Jul 02, 2021: FDA alerts health care professionals and patients to a voluntary recall of varenicline (Chantix) to the warehouse level

Jun 29, 2021: Achieve announces completion of target enrollment of 750 subjects in phase 3 ORCA-2 smoking cessation trial of Cytisinicline

Jun 25, 2021: Pfizer halts distribution of anti-smoking drug after finding carcinogen

Jun 08, 2021: Pfizer Canada announces recall of Champix

Jun 03, 2021: Achieve announces allowance of U.S. patents for dosing and administration of Cytisinicline for the treatment and prevention of addiction

Apr 14, 2021: Achieve announces publication of the ORCA-1 phase 2b clinical trial of Cytisinicline in adult smokers in nicotine and tobacco research

Mar 25, 2021: Achieve announces publication of the RAUORA head-to-head non-inferiority clinical trial comparing Cytisinicline and Chantix (varenicline) in addiction

Oct 27, 2020: Achieve Life Sciences to host smoking cessation key opinion leader virtual roundtable

Oct 07, 2020: Achieve Life Sciences announces start of phase 3 ORCA-2 clinical trial evaluating cytisinicline for smoking cessation

Sep 10, 2020: Achieve Life Sciences announces presentation of Cytisinicline data at the 20th Annual Society for Research on Nicotine & Tobacco Europe (SRNT-E) virtual conference

Jul 31, 2020: Achieve announces Patent granted in the U.S. for novel analogs of Cytisinicline for use in CNS and Addiction Indications

Jun 29, 2020: Achieve announces successful results from the investigator-initiated RAUORA head-to-head non-inferiority clinical trial comparing Cytisinicline and Chantix (varenicline) as a treatment to quit smoking

Dec 09, 2019: Achieve Life Sciences announces completion of meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline smoking cessation phase 3 clinical development program

Oct 24, 2019: Achieve Life Sciences announces presentation of Cytisinicline data at Society for Research on Nicotine & Tobacco Oceania (SRNT-O) Inaugural Conference

Sep 30, 2019: Achieve Life Sciences announces completion of maximum tolerated dose study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2021  
Number of Products under Development by Therapy Areas, 2021  
Number of Products under Development by Indication, 2021  
Number of Products under Development by Companies, 2021  
Products under Development by Companies, 2021  
Number of Products under Investigation by Universities/Institutes, 2021  
Products under Investigation by Universities/Institutes, 2021  
Number of Products by Stage and Mechanism of Actions, 2021  
Number of Products by Stage and Route of Administration, 2021  
Number of Products by Stage and Molecule Type, 2021  
Pipeline by Assuage Pharmaceuticals Inc, 2021  
Pipeline by Ctcbio Inc, 2021  
Pipeline by Jeil Pharmaceutical Co Ltd, 2021  
Pipeline by Kyung Dong Co Ltd, 2021  
Pipeline by Sobrera Pharma AB, 2021  
Pipeline by Sopharma AD, 2021  
Pipeline by Suven Life Sciences Ltd, 2021  
Pipeline by Yuhan Corp, 2021  
Dormant Products, 2021  
Dormant Products, 2021 (Contd..1)  
Discontinued Products, 2021



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

## I would like to order

Product name: Neuronal Acetylcholine Receptor Subunit Alpha 4 - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/N93D3ACCE20DEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N93D3ACCE20DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970